The BioHub - by Avetix

Today on The BioHub, I’m joined by Robert Hoffman, Chief Financial Officer of CytoDyn.Robert is a true industry veteran — with decades ofexperience leading finance and strategy across some of biotech’s most recognizable names, from Arena to Heron and Kintara. Over his career he’s guided IPOs, spin-offs, fundraises, and M&A, all while serving on the boards of multiple biotech companies.Now at CytoDyn, Robert is helping steer the company as itadvances its lead monoclonal antibody program.This conversation is about leadership, staying motivated inbiotech’s toughest cycles, and the big vision for CytoDyn’s future.

Today, we’re joined by an extraordinary leader who has spent her career at the intersection of science, innovation, and human potential — Dr. Sheila Gujrathi.Sheila is a physician, scientist, engineer, and biotech entrepreneur whose journey embodies both precision and purpose. She earned her Bachelor’s degree in Biomedical Engineering and her M.D. from Northwestern University, before completing her residency at Brigham and Women’s Hospital / Harvard Medical School and fellowships in Allergy and Immunology at UCSF and Stanford.Her career has been defined by bold leadership and groundbreaking innovation — from leading global immunology programs at Bristol-Myers Squibb, to serving as Chief Medical Officer at Receptos, where she helped advance the drug Zeposia® to approval for multiple sclerosis and ulcerative colitis. She went on to co-found and serve as CEO of Gossamer Bio, and today she chairs the boards of Ventyx Biosciences and Lila Biologics, while serving as a director at Janux Therapeutics.But beyond her professional success, Sheila is known for her authenticity, her advocacy for diversity and inclusion in biotech, and her belief in leading with empathy, curiosity, and courage. Through her writing and mentorship, she challenges us to bring our whole selves to our work — reminding us that science and leadership are at their best when they’re deeply human.

On this episode we're joined by the Co-Founder & CEO of Tr1X, David de Vries. David and the team are building on the Nobel Prize winning research into T-reg cells of Fred Ramsdell, Shimon Sakaguchi, and Mary Brunkow, pushing that science forward by translating a Type-1 regulatory T cell program into the clinic with one goal - lasting immune balance for patients. Their lead program TRX103 is in ph1/2 trials for GvHD and Refractory Crohn's, whilst they just received another IND clearance for TRX319, an allogeneic CD19 CAR-Tr1 therapy, to tackle Progressive MS. Tr1X pick hard problems on purpose & these indications demonstrate that. David is an impressive leader, having co-founded Arine, and was nominated recently in BioSpace's 40 under 40 list. Tr1X are one to watch, we hope you'll enjoy the episode!

We were honoured to welcome Neha Krishnamohan, onto The BioHub.Neha began her professional journey at Goldman Sachs in theHealthcare Investment Banking Group, focusing on mergers & acquisitions and strategic financings for biotech and med-tech companies. During her time there, she helped execute more than $100 billion in transactions across biopharma, diagnostics and tools.Building on that foundation, Neha then moved into anoperational leadership role in biotech: she served as CFO and Executive Vice President of Corporate Development at Kinnate Biopharma, a precision-oncology company, where she led financial operations, business development and investor relations — working through strategic alternatives that culminated in asset transactions and acquisition. Most recently, she joined Artiva Biotherapeutics, aclinical-stage company focused on off-the-shelf natural-killer (“NK”) cell therapies for autoimmune diseases and cancer, as CFO & EVP Corporate Development (April 2024). Her role is helping drive the company’s growthstrategy, financing, M&A and operational execution as Artiva scales its pipeline.

On this episode of the BioHub Podcast we’re joined by the CEO of Alzinova, Tord Labuda. Alzinova are a Gothenburg-based biotech developing an Alzheimer’s vaccine that's just received FDA IND approval and will soon step into ph2 trials. Alzinova’s products have been developed using their proprietary AβCC peptide™ technology. The technology entails covalent restriction of the amyloid-β (Aβ) peptide so that it only forms the soluble (Aβ) toxins (oligomers/protofibrils) that play a central role in the disease process. Alzinova's mission is to bring true disease-modifying therapy to Alzheimer’s patients. By using the proprietary AβCC technology, Alzinova can develop therapies that are unique in that they target Alzheimer’s disease-driving toxins of Aβ (“oligomers”) specifically.

Welcome to The BiohubJoy Clark, Chief People Officer at Worldwide Clinical Trials, joins The BioHub Podcast to talk about building belonging, leading with purpose, and driving health equity in clinical research. Joy shares her journey from high-growth tech to the CRO world, how Worldwide has cultivated a culture that’s 73% women, and why human-centered leadership matters more than ever.

We were thrilled to welcome, Heather Turner, CEO of LB Pharmaceuticals, onto The BioHub. Heather is a seasoned biotechnology executive with over 25 years of experience driving legal, operational, and strategic excellence across the biopharmaceutical industry. She currently serves as CEO of LB Pharmaceuticals, a clinical-stage company focused on innovative treatments for schizophrenia. Under her leadership, LB recently went public in a landmark IPO, marking a major milestone in the company’s growth journey. Prior to LB, Heather led Carmot Therapeutics through a $3.1 billion acquisition by Roche, expanded teams, and executed transformative financing and strategic initiatives. With deep expertise in navigating complex biotech landscapes, Heather’s insights span corporate strategy, IPOs, and driving innovation in clinical-stage development. We’re excited to hear her perspective on leadership, biotech growth, and the future of medicine

Today, we’re joined by Clarke Atwell, CEO of Claris Biotherapeutics — a company pioneering regenerative biologic therapies with a focus on transforming the field of ophthalmology.Under Clarke’s leadership, Claris has achieved a major milestone with its Series A financing, fueling the company’s mission to advance novel therapies designed to repair and restore vision at the cellular level, and are now in the process of going through there series B round. By combining cutting-edge biology with a deep understanding of ocular disease, Claris is working to address some of the most challenging conditions in eye health.Clarke’s career spans scientific innovation and executive leadership across the biopharma industry, and he now leads Claris through an exciting new chapter of growth and clinical translation.

Today I’m joined by Dr. Maurits Geerlings, President and CEOof NanoCell Therapeutics. Maurits is a true biotech entrepreneur — he’s co-founded and built multiple companies including Actinium Pharmaceuticals, Formula Pharmaceuticals, and Mirata Pharma — and now he’s on a mission to revolutionize in-vivo cell engineering. In this conversation, we dive into Maurits’ journey, the unique structure of NanoCell, the challenges and opportunities in cell therapy right now, and his bold vision for the future of this field.Enjoy and stay tuned.

Amir Inamdar is the Chief Medical Officer at Cybin Inc., bringing more than 20 years of clinical medicine and drug-development experience. Prior to joining Cybin, Amir held senior roles in industry including Senior Medical Director for R&D Neurosciences at AstraZeneca, Medical Director at Takeda Development Centre Europe Ltd., and Director of Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline. He's led global teams in advancing novel therapies across indications such as treatment-resistant depression, narcolepsy, anxiety, schizophrenia, bipolar disorder and substance-use disorders — and steered compounds from preclinical development through first-in-human and proof-of-concept studies